Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 3/20 | 0.46 |
| ▸ | HTR2B | P41595 | 10/20 | 0.46 |
| ▸ | HTR7 | P34969 | 9/20 | 0.46 |
| ▸ | HTR5A | P47898 | 6/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7910683 | 0.86 | HTR5A (0.47) | SLC9A1HTR2BHTR7HTR5ADRD2 | |
| SCHEMBL16502518 | 0.83 | PLA2G2D (0.44) | — | |
| SCHEMBL7919066 | 0.82 | SLC9A1 (0.57) | SLC9A1HTR2BHTR7HTR5ADRD2 | |
| SCHEMBL7921875 | 0.82 | HTR2B (0.55) | SLC9A1HTR2BHTR7HTR5ADRD2 | |
| SCHEMBL7917954 | 0.81 | HTR2B (0.52) | SLC9A1HTR2BHTR7HTR5ADRD2 | |
| SCHEMBL7918771 | 0.80 | HTR2B (0.51) | SLC9A1HTR2BHTR7HTR5ADRD2 | |
| SCHEMBL7917542 | 0.80 | HTR5A (0.55) | SLC9A1HTR2BHTR7HTR5A | |
| SCHEMBL7918264 | 0.80 | SLC9A1 (0.49) | SLC9A1HTR2BHTR7HTR5ADRD2 | |
| SCHEMBL7918294 | 0.79 | HTR2B (0.51) | SLC9A1HTR2BHTR7HTR5ADRD2 | |
| SCHEMBL16502778 | 0.79 | SLC9A1 (0.51) | SLC9A1HTR2BHTR7HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| EP-2394987-A1 | ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010090304-A1 | ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | HTR5A, HTR2A, HTR1A | SLC9A1 1256/4885HTR2B 5/4885HTR7 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.